Abstract
Neutral endopeptidase 24.11 (NEP) is a cell-surface enzyme expressed by prostatic epithelial cells that cleaves and inactivates neuropeptides implicated in the growth of androgen-independent prostate cancer (PC). We report that NEP expression and catalytic activity are lost in vitro in androgen-independent but not androgen-dependent PC cell lines. In vivo, NEP protein expression is commonly decreased in cancer cells of metastatic PC specimens from patients with androgen-independent but not androgen-dependent PC. Overexpression of NEP in androgen-independent PC cells or incubation with recombinant NEP inhibits PC cell growth. Furthermore, in androgen-dependent PC cells, expression of NEP is transcriptionally regulated by androgen and decreases with androgen withdrawal. These data suggest that decreased NEP expression, common in androgen-independent PCs, is facilitated by the elimination of androgens, and that NEP loss plays an important role in the development of androgen-independent PC by allowing PC cells to use mitogenic neuropeptides as an alternate source to androgen in order to stimulate cell proliferation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bologna, M., Festuccia, C., Muzi, P., Biordi, L. & Ciomei, M. Bombesin stimulates growth of human prostatic cells in vitro. Cancer 63, 1714–1720 (1989).
Sehgal, I. et al. Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer. Proc. Natl. Acad. Sci. USA 91, 4673–4677 (1994).
Nelson, J.B. et al. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res. 56, 663–668 (1996).
Abrahamsson, P.A. & Di Sant'Agnese, P.A. Neuroendocrine cells in the human prostate gland. J. Androl. 14, 307–309 (1993).
Nelson, J.B. et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nature Med. 1, 944–949 (1995).
Cussenot, O. et al. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J. Urol. 155, 1340–1343 (1996).
Reile, H., Armatis, P.E. & Schally, A.V. Characterization of high-affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC-3 DU-145: Internalization of receptor bound 125l-(Tyr4) bombesin by tumor cells. Prostate 25, 29–38 (1994).
Pinski, J., Halmos, G. & Schally, A.V. Somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of an-drogen-independent DU-145 human prostate cancer cell line in nude mice. Cancer Lett 71, 189–196 (1993).
Aprikian, A.G. et al. Neuroendocrine differentiation in metastatic prostatic adenocarcinoma. J. Urol. 151, 914–919 (1994).
Cohen, R., Glezerson, O. & Haffejee, Z. Neuro-endocrine cells: Prognostic parameter in prostate cancer. Br. J. Urol. 68, 57–62 (1991).
Kenny, A.J., O'Hare, M.J. & Gusterson, B.A. Cell-surface peptidases as modulators of growth and differentiation. Lancet 2, 785–787 (1989).
Shipp, M.A. & Look, A.T. Hematopoietic differentiation antigens that are membrane-associated enzymes: Cutting is the key! Blood 84, 1052–1070 (1993).
Shipp, M.A. et al. Common acute lymphoblastic leukemia antigen (CALLA) is active neutral endopeptidase 24.11 (“enkephalinase”): direct evidence by cDNA transfection analysis. Proc. Natl. Acad. Sci. USA 86, 297–301 (1989).
Checler, F., Emson, P.C., Vincent, J.P. & Kitabgi, P. Inactivation of neurotensin by rat brain synaptic membranes: Cleavage at the Pro10-Tyr11 bond by endopeptidase 24.11 (enkephalinase) and a peptidase different from proline-endopeptidase. J. Neurochem. 43, 1295–1301 (1984).
Kenny, A.J. Endopeptidase-24.11: putative substrates and possible roles. Biochem Soc. Trans. 21, 663–668 (1993).
Shipp, M.A. et al. CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. Proc. Natl. Acad. Sci. USA 88, 10662–10666 (1991).
Nanus, D.M., Papandreou, C.N. & Albino, A.P. Cell-Surface Peptidases in Health and Disease (eds. Kenny, J. & Boustead, CM.) 353–369 (BIOS Scientific Publishers, Oxford, 1997).
Fournie-Zaluski, M.C. et al. Inhibitory potency of various peptides on enkephalinase activity from mouse striatum. Biochem. Biophys. Res. Commun. 91, 130–135 (1979).
Matsas, R., Kenny, A. & Turner, A.J. The metabolism of neuropeptides: The hydrolysis of peptides, including enkephalins, tacykinins and their analogues, by en-dopeptidase-24.11. Biochem. J. 223, 433–440 (1984).
Gschwend, J.E., Fair, W.R. & Powell, C.T. Evaluation of the tetracycline-repressible transactivator system for inducible gene expression in human prostate cancer cell lines. Prostate 33, 166–176 (1997).
Gossen, M. & Bujard, H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA 89, 5547–5551 (1992).
Veldscholte, J., Berrevoets, C.A., Brinkmann, A.O., Grootegoed, J.A. & Mulder, E. Anti-androgens and the mutated androgen receptor of LNCaP cells: Differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry 31, 2393–2399 (1992).
Klocker, H. et al. Basic Research in Urologic Oncology (eds. Luciani, L, Debruyne, F.M.J. & Schalken, J.A.) 28–40 (Karger, Basel, 1996).
Taplin, M.E. et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 332, 1393–1398 (1995).
Ishimaru, F. & Shipp, M.A. Analysis of the human CD10/neutral endopeptidase 24.11 promoter region: Two separate regulatory elements. Blood 85, 3199–3207 (1995).
Israeli, R.S., Powell, C.T., Corr, J.G., Fair, W.R. & Heston, W.D. Expression of the prostate-specific membrane antigen. Cancer Res. 54, 1807–1811 (1994).
Borson, D.B. & Gruenert, D.C. Glucocorticoids induce neutral endopeptidase in transformed human tracheal epithelial cells. Am. J. Physiol. 260, L83–L89 (1991).
Casey, M.L., Smith, J.W., Nagai, K., Hersh, L.B. & MacDonald, P.C. Progesterone-regulated cyclic modulation of membrane metalloendopeptidase (enkephalinase) in human endometrium. J. Biol. Chem. 34, 23041–23047 (1991).
Scher, H.I., Mazumdar, M. & Kelly, W.K. Clinical trials in relapsed prostate cancer: Defining the target. J. Natl. Cancer Inst. 88, 1623–1634 (1997).
McDonnell, T.J., et al. Expression of the proto-oncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 52, 6940–6944 (1992).
Bookstein, R., MacGrogan, D., Hilsenbeck, S.G., Sharkey, F. & Allred, D.C. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res. 53, 3369–3373 (1993).
Steiner, M.S. Review of peptide growth factors in benign prostatic hyperplasia and urological malignancy. J. Urol. 153, 1085–1096 (1995).
Duncan, M.D., Harmon, J.W. & Duncan, K.L.K. Actin disruption inhibits bombesin stimulation of focal adhesion kinase (pp125(FAK)) in prostate carcinoma. J. Surg. Res. 63, 359–363 (1996).
Rozengurt, E. Convergent signalling in the action of integrins, neuropeptides, growth factors and oncogenes. Cancer Surv. 24, 81–96 (1995).
Frame, K.L., Patton, K., Reed, M.J., Ghilchik, M.W. & Parish, D.C. Angiotensin-converting enzyme and enkephalinase in human breast cyst fluid. Br. J. Cancer 74, 807–813 (1996).
Bogenrieder, T. et al. Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissue. Prostate 33, 225–232 (1997).
Papandreou, C.N., Bogenrieder, T., Scher, H.I., Albino, A.P. & Nanus, D.M. Expression and sequence analysis of the SD11/WAF1/CIP1/p21 tumor suppressor gene in prostate cancer cell lines. Int. J. Oncol. 8, 1237–1241 (1996).
Orlowski, M., Michaud, C. & Chu, T.G. A soluble metalloendopeptidase from rat brain. Purification of the enzyme and determination of specificity with synthetic and natural peptides. Eur. J. Biochem. 135, 81–88 (1983).
Nanus, D.M. et al. Transformation of human kidney proximal tubule cells by ras-containing retroviruses: Implications for tumor progression. J. Exp. Med. 169, 953–972 (1989).
Hoffman, A.D. et al. Expression of retinoic acid receptor beta in human renal cell carcinomas correlates with sensitivity to the antiproliferative effect of 13-cis retinoic acid. Clin. Cancer Res. 2, 1077–1082 (1996).
Nabeya, Y., et al. The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. Int. J. Cancer 64, 1–10 (1995).
Cohen, A.J., etal. Neutral endopeptidase variable expression in human lung, inactivation in lung cancer, and modulation of peptide induced calcium flux. Cancer Res. 56, 831–839 (1996).
Nanus, D.M. et al. Flow cytometry as a predictive indicator in patients with operable gastric cancer. J. Clin. Oncol. 7, 1105–1112 (1989).
Nanus, D.M. et al. Molecular cloning of the human kidney differentiation antigen gp160: Human aminopeptidase A. Proc. Natl. Acad. Sci. USA 90, 7069–7073 (1993).
Greenberg, M.E. & Bender, T.P. Identification of newly transcribed RNA. Current Protocols in Molecular Biology (eds. Ausubel, F.M., et al.) 4.10.1–4.10.4 (Wiley Interscience, Boston, 1993).
D'Adamio, L, Shipp, M.A., Masteller, E.L. & Reinherz, E.L. Organization of the gene encoding common acute lymphoblastic leukemia antigen (neutral endopeptidase 24.11): multiple miniexons and separate 5′ untranslated regions. Proc. Natl. Acad. Sci. USA 86, 7103–7107 (1989).
Nanus, D.M. et al. Expression of basic fibroblast growth factor in primary human renal tumors: Correlation with poor survival. J. Natl. Cancer Inst. 85, 1597–1599 (1993).
Sunday, M.E., Hua, J., Torday, J.S., Reyer, B. & Shipp, M.A. CD/10 neutral endopeptidase 24.11 in developing human fetal lung. J. Clin. Invest. 90, 2517–2525 (1992).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Papandreou, C., Usmani, B., Geng, Y. et al. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med 4, 50–57 (1998). https://doi.org/10.1038/nm0198-050
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nm0198-050
This article is cited by
-
SOCS1 favors the epithelial-mesenchymal transition in melanoma, promotes tumor progression and prevents antitumor immunity by PD-L1 expression
Scientific Reports (2017)
-
Long-term neprilysin inhibition — implications for ARNIs
Nature Reviews Cardiology (2017)
-
Epigenetic suppression of neprilysin regulates breast cancer invasion
Oncogenesis (2016)
-
Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity
Journal of Cancer Research and Clinical Oncology (2016)
-
Genetic homogeneity but IgG subclass–dependent clinical variability of alloimmune membranous nephropathy with anti-neutral endopeptidase antibodies
Kidney International (2015)